The cost plus fixed fee (cpff) to to refurbish and improve NCI frederick infrastructure will have a base and three (3) options.
Ended Awarded Last action
- Contract number
- 75N91023F00024
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $7,999,585
Award facts
- Contract value 100% obligated
- $7,999,585.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Default | -$449,559 | |
| Other Administrative Action | $0 | |
| Terminate for Convenience | $0 | |
| Funding Only Action | $37,954 | |
| Other Administrative Action | $0 | |
| Original award | $8,411,190 |
About this award
Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. and Federally Funded Research and Development Center (FFRDC) contractor, was awarded a Cost Plus Fixed Fee (CPFF) delivery order by the National Cancer Institute (NCI) on September 27, 2023, to refurbish and improve NCI Frederick infrastructure. The contract has a ceiling value of $7.999 million, includes a base period and three optional periods, with ultimate completion scheduled for July 10, 2026. No set-aside designation was applied to this award. The work will be performed in Frederick, Maryland, where Leidos Biomedical Research maintains significant research and operational facilities supporting the NCI's scientific mission.
This delivery order reflects Leidos Biomedical Research's established role as a primary service provider to the National Cancer Institute and National Institutes of Health, supporting the agency's facility infrastructure and research operations. The CPFF contract structure provides flexibility for addressing facility improvement requirements while the inclusion of optional periods allows the NCI to extend services based on performance and evolving facility needs. The award aligns with federal government efficiency initiatives, as noted in the implementing Executive Order language dated March 19, 2025, demonstrating the contract's integration with broader federal cost management objectives.
Quick answers
Who was awarded contract 75N91023F00024?
75N91023F00024 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 27, 2023.
How much is contract 75N91023F00024 worth?
The government has obligated $7,999,585 on 75N91023F00024.
Is contract 75N91023F00024 an order under another contract?
Yes. 75N91023F00024 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91023F00024 competed?
The extent of competition for 75N91023F00024 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award